{"id":"https://openalex.org/W2559999375","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","title":"Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.","display_name":"Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2559999375","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","mag":"2559999375"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.e11573","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021504145","display_name":"Natalie Faye Sinclair","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Sinclair","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012098015","display_name":"MM Abu-Khalaf","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. M. Abu-Khalaf","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073112596","display_name":"Bachir Joseph Sakr","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. J. Sakr","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039026806","display_name":"Tina Rizack","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Rizack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002012448","display_name":"Donald R. Lannin","orcid":"https://orcid.org/0000-0001-8700-7675","observed_orcids":["https://orcid.org/0000-0001-8700-7675"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. R. Lannin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082664275","display_name":"Jennifer S. Gass","orcid":"https://orcid.org/0000-0002-9762-7912","observed_orcids":["https://orcid.org/0000-0002-9762-7912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. S. Gass","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112045860","display_name":"Rochelle Strenger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Strenger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038666593","display_name":"V Bossuyt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Bossuyt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073834752","display_name":"Mary Anne Fenton","orcid":"https://orcid.org/0000-0002-6467-5352","observed_orcids":["https://orcid.org/0000-0002-6467-5352"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Fenton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021514634","display_name":"Lyndsay N. Harris","orcid":"https://orcid.org/0000-0002-9774-6719","observed_orcids":["https://orcid.org/0000-0002-9774-6719"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Harris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111781257","display_name":"W. M. Sikov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. M. Sikov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"e11573","last_page":"e11573"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11134","display_name":"Breast Lesions and Carcinomas","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.8930000066757202},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.9649999737739563},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8339999914169312},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.9020000100135803},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8149999976158142},{"id":"https://openalex.org/keywords/residual-cancer-burden","display_name":"residual cancer burden","score":0.8920000195503235},{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.9419999718666077},{"id":"https://openalex.org/keywords/circulating-endothelial-cells","display_name":"circulating endothelial cells","score":0.8999999761581421},{"id":"https://openalex.org/keywords/doxorubicin-and-cyclophosphamide","display_name":"doxorubicin-cyclophosphamide","score":0.7590000033378601},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.7020000219345093},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.6460000276565552}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9308120012283325},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6080461740493774},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5983282327651978},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5250035524368286},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.4694886803627014},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4588696360588074},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.43266281485557556},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.41166579723358154},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.39776021242141724},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.33740711212158203},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32368654012680054},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.14071187376976013}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.e11573","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11573","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6800000071525574}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2602846211","https://openalex.org/W2246526095","https://openalex.org/W2240914075","https://openalex.org/W2603858455","https://openalex.org/W4379285881","https://openalex.org/W2602854969","https://openalex.org/W2465958314","https://openalex.org/W2165375210","https://openalex.org/W4411289096","https://openalex.org/W2395607435"],"abstract_inverted_index":{"e11573":[0],"Background:":[1],"To":[2],"evaluate":[3],"CbwAbAv":[4,254],"NAC":[5,275],"in":[6,96,105,156,265],"HER2-":[7,14],"BrCA.":[8],"Methods:":[9],"60":[10],"patients":[11],"(pts)":[12],"with":[13,153,180,223,226,299],"(IHC":[15],"0-1+":[16],"or":[17,36,237,276,292],"FISH":[18],"<2.0)":[19],"invasive":[20,94],"BrCA,":[21],"clinical":[22],"stage":[23],"IIA-IIIC,":[24],"will":[25,305],"undergo":[26],"research":[27],"biopsies/MRI":[28],"pre":[29],"and":[30,61,76,109,117,149,162,178,201,259],"post":[31],"\u201cpriming\u201d":[32],"doses":[33],"of":[34,93,146,279],"Av":[35,48,69],"wAb,":[37],"then":[38],"receive":[39,68],"q3wk":[40],"Cb":[41,151],"AUC":[42],"6,":[43],"wAb":[44,148],"100":[45],"mg/m2":[46],"+":[47,54,98],"5":[49],"mg/kg/week":[50],"x":[51,64,70,78],"12":[52,330,348],"weeks":[53],"(cohort":[55,57,80],"1)/-":[56],"2)":[58,81],"dose-dense":[59],"doxorubicin":[60],"cyclophosphamide":[62],"(ddAC)Av":[63],"4.":[65],"Post-op,":[66],"pts":[67,128,214],"34":[71],"weeks;":[72],"radiation,":[73],"endocrine":[74],"Rx,":[75],"ddACAv":[77],"4":[79,150],"at":[82,115,230,290],"MD":[83],"discretion.":[84],"Endpoints":[85],"include":[86,171],"pathologic":[87,262,301],"complete":[88],"response":[89],"(pCR":[90],"-":[91,159,165],"absence":[92],"disease":[95],"breast":[97],"axillary":[99],"nodes),":[100],"residual":[101],"cancer":[102],"burden":[103],"(RCB)":[104],"non-pCRs,":[106],"dose":[107,154],"delivery":[108],"toxicities.":[110],"Circulating":[111],"tumor/endothelial":[112],"cells":[113],"(CTC/CEC)":[114],"baseline":[116,231,291],"after":[118,238,293],"priming":[119,239],"are":[120,207],"analyzed":[121],"using":[122],"the":[123,277],"Veridex":[124],"platform.":[125],"Results:":[126],"39":[127,317],"(median":[129],"age":[130],"47;":[131],"range":[132],"25-69),":[133],"21":[134,322,327,350],"hormone":[135],"receptor":[136],"positive":[137],"(HR+),":[138],"18":[139,324,339,359],"triple-negative":[140],"(TN)":[141],"have":[142],"received":[143],"a":[144],"median":[145],"11":[147,345],"doses,":[152],"reductions":[155],"25%":[157],"(wAb":[158],"neutropenia":[160,190],"[ANC])":[161],"14%":[163],"(Cb":[164],"thrombocytopenia":[166],"(tcp)).":[167],"Grade":[168],"3/4":[169],"toxicities":[170],"ANC":[172],"(43%/39%),":[173],"tcp":[174],"(18%/7%),":[175],"transaminitis,":[176],"nausea":[177],"hypokalemia,":[179],"no":[181],"grade":[182,202],">2":[183],"neuropathy.":[184],"Serious":[185],"adverse":[186],"events":[187],"(SAEs):":[188],"febrile":[189],"(2),":[191],"altered":[192],"mental":[193],"status,":[194],"anemia,":[195],"post-mastectomy":[196],"tissue":[197],"necrosis,":[198],"GI":[199],"bleed":[200],"2":[203,338,353],"proteinuria.":[204],"Pathologic":[205],"responses":[206],"tabulated":[208],"below":[209],"(Table).":[210],"At":[211],"baseline,":[212],"few":[213],"(19%)":[215],"had":[216],"identifiable":[217],"CTC,":[218],"which":[219],"did":[220],"not":[221],"correlate":[222],"response.":[224,302],"Pts":[225],"higher":[227],"CEC":[228,288],"levels":[229,289],"(median,":[232,240],"22":[233],"vs.":[234,242],"11,":[235],"p=.087)":[236],"31":[241],"14.5,":[243],"p=.035)":[244],"were":[245],"more":[246],"likely":[247],"to":[248],"achieve":[249],"RCB":[250,312,314],"0-1.":[251],"Conclusions:":[252],"Neoadjuvant":[253],"is":[255],"generally":[256],"well":[257],"tolerated":[258],"yields":[260],"encouraging":[261],"responses,":[263],"especially":[264],"TN":[266,358],"pts.":[267],"Differences":[268],"between":[269],"cohorts":[270],"suggest":[271],"that":[272],"longer":[273],"duration":[274],"use":[278],"non-cross":[280],"resistant":[281],"regimens":[282],"may":[283,296],"improve":[284],"pCR":[285,309],"rate.":[286],"Higher":[287],"initial":[294],"therapy":[295],"be":[297,306],"associated":[298],"improved":[300],"Updated":[303],"results":[304],"presented.":[307],"n":[308],"IA/IB":[310],"II-III":[311],"0-1":[313],"2-3":[315],"Total":[316],"13":[318],"(33%)":[319,347],"9":[320],"17":[321],"(54%)":[323],"Cohort":[325,337],"1":[326,342,363],"(12":[328],"TN)":[329,341],"(57%)":[331],"3":[332,351,366],"6":[333,336,344,346,355],"15":[334,357,364],"(71%)":[335],"(6":[340],"(6%)":[343],"HR+":[349],"(14%)":[352],"16":[354],"(29%)":[356],"10":[360],"(56%)":[361],"7":[362],"(83%)":[365]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-12-16T00:00:00"}